Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

NICE rejects ustekinumab

The National Institute for Health and Care Excellence has issued final guidance that does not recommend ustekinumab for psoriatic arthritis, alone or in combination with methotrexate. The independent appraisal committee concluded that ustekinumab is less effective than tumour necrosis factor alpha inhibitors and is not a cost-effective option. Patients currently receiving ustekinumab can continue receiving the medicine until they and their clinicians consider it appropriate to stop.

Citation: The Pharmaceutical Journal URI: 11138677

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.


Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.